Summary
The association between the single nucleotide polymorphisms (SNPs) in −174G/C and −634C/G of interleukin-6 (IL-6) promoter region and prostate cancer was examined in the population of Han people in Hubei region. TaqMan PCR was employed for the gene-typing of −174G/C and −634C/G in promoter region of IL-6 gene to compare the prostate cancer patients and normal controls in terms of genotype frequency, allele frequency and risk of prostate cancer. Enzyme-linked immunosorbent assay (ELISA) was used for the detection of IL-6 concentration in peripheral blood of the patients with prostate cancer and the relationship between the IL-6 level and the genotype was studied. Our results showed that in all the subjects, the genotype of genetic locus −174G/C was found to be GG and no CG and CC were observed. There was a significant difference in gene frequency of GG, CG and CC of −634C/G and allele frequency of G and C between prostate cancer patients and normal controls (P<0.05) and the gene frequency of GG+CG increased with the clinical stages and pathological grades of prostate cancer. The IL-6 level in GG+CG group was significantly higher than that in CC group. It was concluded that no SNP in −174G/C IL-6 promoter region was found in the population of Han people in Hubei region. The SNP in −634C/G was, to some extent, associated with the development and progression of prostate cancer. The population with GG+CG genetype has higher risk for prostate cancer.
Similar content being viewed by others
References
Walsh P C, Retik A B, Vaughan E D et al. Campbell’s urology, 8th ed. Philadelphia: Saunders. 2002.3003
Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin, 2003,53(1):5–26
Habuchi T. Common genetic polymorphisms and prognosis of sporadic cancers: prostate cancer as a model. Future Oncol, 2006,2(2):233–245
Schneider S, Roessli D, Excoffier L. Arlequin, a software for population genetics data analysis. Ver2.000. Geneva: Genetics and Biometry Lab, Department of Anthropology, University of Geneva, 1997.
William S, Mark S, Jasbir S S. 1.9 Å crystal structure of interleukin-6: implications for a novel mode of receptor dimerization and signaling. EMBO, 1997,16(5):989–997
Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol, 1993,54(1):1–78
Dominique S M, Sarah E D, Sonja I B et al. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res, 2006,66(8):4525–4530
Xu J F, James L, Fredrik W et al. The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk. Cancer Epidemiol Biomarkers Prev, 2005,14(11):4525–4530
Cox E D, Hofference S C, Dimercurio B S et al. Cytokine polymorphic analyses indicate ethnic difference in the allelic distribution of interlerkin-2 and interlerkin-6. Transp lantation, 2001,72(4):720–726
Zhai R, Liu G, Yang C et al. The G to C polymorphism at −174 of the interleukin-6 gene is rare in a southern Chinese population. Pharmacogenetics, 2001,11:699–701
Liu X J, Chen X M, Sun X F et al. Polymorphisms of interleukin-6 gene promoter region in healthy population in Beijing City of China: comparison with Asian descendants and Cancasian. Chin J Clin Rehabilitation (Chinese), 2005,9(19):116–118
Lim C S, Zheng S, Kim Y S et al. The −174 G to C polymorphism of interleukin-6 gene is very rare in Koreans. Cytokine, 2002,19:52–54
McCarron S L, Edwards S, Evans P R et al. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res, 2002,62:3369–3372
Kitamura A, Hasegawa G, Obayashi H et al. Interleukin-6 polymorphism (−634 C/G) in the promoter region and the progression of diabetic nephropathy in Type 2 diabetes. Diabetic Med, 2002,19(12):1000–1005
Author information
Authors and Affiliations
Additional information
Shixin BAO, male, born in 1974, Doctoral Candidate
Rights and permissions
About this article
Cite this article
Bao, S., Yang, W., Zhou, S. et al. Relationship between single nucleotide polymorphisms in −174G/C and −634C/G promoter region of interleukin-6 and prostate cancer. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 28, 693–696 (2008). https://doi.org/10.1007/s11596-008-0618-3
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-008-0618-3